NNCSF
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.03 | $102M | $4M |
| 2025 Q4 | 0.04 | $105M | $20M |
| 2024 Q2 | 0.03 | $94M | $15M |
| 2024 Q4 | 0.03 | $89M | $12M |
| 2023 Q2 | 0.02 | $80M | $8M |
| 2023 Q4 | 0.03 | $84M | $14M |
| 2022 Q2 | 0.03 | $82M | $6M |
| 2022 Q4 | -0.00 | $60M | $4M |